MVRIX
Latest round
- Series B
Last raised
- Sep 2026
Total raised
- $5.9M
Investors
- 5
About MVRIX
, Ltd.. doing business as MVRIX, with a mission to develop innovative therapeutics through advanced biotechnology and protein-engineering research. Since its establishment, the company has rapidly built three core platform technologies and expanded its network through collaborations with companies, universities, and research institutes. MVRIX specializes in targeted mRNA delivery, in vivo CAR-T therapies, recombinant botulinum toxins, and biologics development. The company has accumulated a substantial patent portfolio and has received multiple government-backed R&D and startup support programs. The company focuses on developing next-generation therapeutic platforms based on protein engineering and gene therapy technologies. Its flagship technologies include the Navibody Platform, which enables targeted mRNA delivery with enhanced specificity and manufacturing efficiency; the In vivo CAR-T Platform, designed to realize next-generation cell therapies directly within the body; and the rBoNT Platform, a recombinant botulinum toxin technology aimed at creating faster, safer, and longer-lasting toxin therapeutics. In addition, MVRIX conducts research in biologics discovery, gene therapy delivery systems, and novel therapeutic modalities. The company's revenue is generated through the development and commercialization of proprietary biotechnology platforms, research collaborations, licensing agreements, technology transfer transactions, and future commercialization of therapeutic candidates. A notable example is the licensing-out agreement of its MBT-002 recombinant botulinum toxin pipeline to Eyegene in 2025, demonstrating the company's strategy of monetizing its platform technologies through partnerships and licensing deals.
Who invested in MVRIX
5 investors across 1 round
See all investors in MVRIX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Sep 4, 2026
Amount
$5.9M
Investors
Questions about MVRIX
Who invested in MVRIX?
MVRIX has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MVRIX raised?
MVRIX has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did MVRIX last raise money?
MVRIX's most recent round on record is a Series B, in Sep 2026.
What does MVRIX do?
MVRIX is a biotechnology company.
Where is MVRIX headquartered?
MVRIX is headquartered in Hwaseong, South Korea.
Which VCs invest in companies like MVRIX?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at MVRIX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like MVRIX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.